With Evernow, the first choice may be how to access care rather than which hormone to use. Its progesterone page describes clinician-guided treatment, while its service pages offer both ongoing membership and individual video visits. Someone coordinating estrogen and progesterone needs to understand what remains available under each arrangement and who reviews the relationship between the medicines.
The Uterus Question is part of the CoreAge Rx promotional publishing network. CoreAge holds our first commercial position, without a claim that it delivers better clinical results than Evernow. This review is based on public provider and primary medical sources, not a purchased appointment, patient survey or inspection of dispensing practices.
What confirms that progesterone is within the service scope?
Evernow has a dedicated progesterone treatment page describing care through video visits or messaging. It discusses progesterone in hormone plans and directs readers toward clinical assessment. Its broader service explanation describes prescriptions being sent to a pharmacy or delivered when included in a care plan.
That establishes a relevant service to investigate, not a prescription guarantee or a confirmed medicine for a particular applicant. Ask how the clinician reviews an estrogen prescription from another practice. The care comparison evaluates those responsibilities across providers without treating access to a portal as evidence that every part of a plan has already been reconciled.
Resolve the progesterone FAQ’s product-description errors
The current public FAQ contains mismatched answers: an FDA-approval question is followed by hair-regrowth language, and another answer mentions generic equivalents of Provera. The page also names Prometrium but calls it a tablet. These are specific publishing problems that make the page insufficient as an exact medication record. Evernow page.
The distinction is substantive. Provera’s label identifies medroxyprogesterone acetate tablets; Prometrium’s current label identifies progesterone capsules. They are not simply two names for the same active ingredient. We cannot infer a prescribing error from website copy, but we can advise asking the clinician and pharmacist to confirm the actual medicine, form and rationale before relying on those answers.
Keep surgical history and estrogen identity together
The progesterone page presents uterine protection as one treatment purpose. The FDA overview explains the relationship between systemic estrogen and an added progestogen in the relevant clinical setting. That broad explanation does not settle a plan for someone with prior surgery or a different estrogen product.
Bring the complete medication names and any operative information that clarifies what procedure was performed. Our hysterectomy-questions guide and systemic-estrogen guide identify useful discussion points. If the estrogen is a vaginal product, its identity still matters; the local-treatment guide explains why a route label alone should not decide the answer.
Membership has several prices, not one universal monthly charge
Evernow’s FAQ lists month-to-month membership at $49, a three-month plan at $129 and a twelve-month plan at $420. The advertised $35 monthly figure is the twelve-month plan’s equivalent. Ask about actual billing and cancellation conditions rather than assuming that every membership costs $35 with month-to-month flexibility.
Its hormone-therapy page says medication costs are separate. Optional video visits may also involve insurance cost-sharing or the published $150 self-pay visit fee. Those distinctions prevent the membership headline from being mistaken for a complete estrogen-and-progesterone supply. Confirm the proposed medicine costs and any outside services before comparing the total with another provider.
A one-time visit’s access period is not a medication supply
The pay-per-visit description includes access to prescriptions and the care platform for 90 days. That refers to the service arrangement; it is not a promise of 90 days of a specific medication or automatic clinical approval. Ask what follow-up is available within that period and what happens if an unresolved concern continues afterward. Access description.
The FAQ lists a $150 self-pay video visit and says commercial coverage varies. It also says Medicare and Medicaid coverage are not currently supported, while membership fees are not insurance-covered. Those statements should not be expanded into an unverified claim that every beneficiary is ineligible for every self-pay service; eligibility and payment should be confirmed for the chosen arrangement.
Messaging availability is not an urgent assessment guarantee
Evernow advertises secure messaging within ongoing care and describes typical response expectations in its FAQ. We have not measured those responses. Being able to send a message at any hour does not establish that a clinician is immediately available to assess new bleeding or another urgent concern. Evernow service FAQ.
ACOG’s bleeding guidance supports evaluation of bleeding after menopause. Ask which clinician will arrange any necessary in-person care and how results will return to the hormone prescriber. Our unexpected-bleeding guide helps make that pathway explicit. Do not assume a portal message, a prescription renewal or another shipment resolves the clinical question.
The pharmacy choice should preserve the correct product record
Evernow describes local-pharmacy and partner-pharmacy fulfillment, with restrictions depending on the prescription. Some medicines may require a particular fulfillment route or cash payment. A choice advertised generally may therefore not apply to every proposed product. Pharmacy and payment FAQ.
After the clinician identifies the medicine, ask the pharmacy to confirm its name, form and ingredients, particularly if an allergy or previous reaction matters. A website list is not enough to settle those details. The CoreAge review has different formulation unknowns; our commercial affiliation does not resolve either service’s unanswered product questions.
Judge the coherence of the resulting care plan
The useful result is one explanation connecting the treatment goal, surgical history, estrogen product and reason for any added medicine. It should identify who reviews changes, what follow-up the selected access model includes and where concerns go when they require assessment outside the platform. Neither membership length nor a reassuring testimonial establishes that coherence.
Evernow’s public information supports a current menopause and progesterone care offering, with clear cost distinctions and copy errors that merit clarification. This review does not determine which medicine a reader needs or provide a treatment schedule. Use it to prepare a more precise conversation and to obtain a reliable prescription record from the professionals involved.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- Evernow: progesterone treatment page and product FAQProvider treatment page; full public HTML checked · Checked 2026-09-27
- Evernow: how membership and pay-per-visit care workProvider service terms · Checked 2026-09-27
- Pfizer: Provera medroxyprogesterone acetate tablet labelingExact prescription product labeling; used for ingredient identity · Checked 2026-09-27
- DailyMed: current Acertis Prometrium progesterone capsule record, updated July 23, 2026Exact prescription product labeling · Checked 2026-09-27
- FDA: current hormone therapy categories and warning changesFederal regulator patient information · Checked 2026-09-27
- Evernow: care, insurance, membership and pharmacy FAQProvider service and payment terms · Checked 2026-09-27
- Evernow: hormone therapy and separate medication costsProvider treatment page; full public HTML checked · Checked 2026-09-27
- ACOG: Perimenopausal Bleeding and Bleeding After MenopauseMedical society patient guidance · Checked 2026-09-27